Abbott has announced that it has reached a significant settlement agreement with DexCom, Inc., resolving all ongoing patent disputes between the two companies related to continuous glucose monitoring ...

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom DXCM revealed 8 unusual trades. Delving into the details, we found 37% of traders were ...

In order from steepest decline to narrowest, the five unloved were Intel (NASDAQ: INTC), MongoDB (NASDAQ: MDB), Biogen (NASDAQ: BIIB), DexCom (NASDAQ: DXCM), and Microchip Technology (NASDAQ ...

Being insulin-treated is one of the requirements for typical CGM devices like DexCom's G6, and not all of those with type 2 diabetes meet this condition. So DexCom's patient population is ...

DexCom faces challenges in 2024 due to competition ... like 6% from discounting that was reached quickly due to a fast migration to G7 from G6. This will become a tailwind in 2025 Q3, as this ...

Unless you’re an advocate for health tech or a diabetic like me, you may not have heard of Dexcom or Abbott, the two companies that form an oligopoly in the CGM space. Yet, you’re probably ...

DexCom, Inc. (DXCM), headquartered in California, is a leading player in the medical devices sector. Valued at a market cap of $30.4 billion, the company specializes in continuous glucose ...

DexCom DXCM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ...

Outside of Pickens, Pittsburgh lacks high-end talent and production at receiver. Calvin Austin III, Van Jefferson, and Mike Williams have shown flashes, but none are capable of being a reliable ...

South Carolina wide receiver Jared Brown is returning to the Gamecocks for his final season, per Wes Mitchell at On3 Sports. The 5-foot-11 and 195 pound redshirt senior transferred to the ...